首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease
【24h】

Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease

机译:纳米医疗治疗阿尔茨海默病的神经治疗应用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Alzheimer's disease (AD) is a progressive, irreversible, fatal brain disease which disturbs cognitive functions. It affects 35 million people worldwide and the number of people suffering may increase to 100 million by 2050 if no effective treatments are available. The present treatment improves cognitive functions and provide temporary symptomatic relief, but do not stop or delay the disease progression. Moreover, they are mainly available as conventional oral dosage forms and these conventional oral medications lack brain specificity and also produce side effects which leads to poor patient compliance. Brain drug targeting by nanomedicines is a promising approach to improve brain targeting specificity, brain bioavailability and patient compliance. The present review discuses about the currently available pharmacotherapy for AD and the neurotherapeutic applications as well as the advancements of nanomedicine for treating AD. It also highlights the recent advancements of various nanomedicines containing phytopharmaceuticals for treating AD. It is believed that nanomedicines containing approved drugs can be transformed into the clinics hence improve the life style of AD patients.
机译:阿尔茨海默病(AD)是一种进步,不可逆,致命的脑病,其扰乱认知功能。它影响了全球3500万人,如果没有有效的治疗,那么遭受的人数可能会增加到2050年的1亿。目前的治疗改善了认知功能并提供暂时的症状缓解,但不会停止或延迟疾病进展。此外,它们主要作为常规口服剂型和这些常规口服药物缺乏脑特异性,并且还产生副作用,这导致患者依从性差。纳米胺的脑药靶向是一种有希望的方法,可以改善脑靶向特异性,脑生物利用度和患者遵守性。目前审查关于AD和神经治疗应用的目前可用的药物疗法以及纳米医疗的进步治疗广告。它还强调了含有植物治疗广告的植物药物的各种纳米海内西亚的最新进步。据信,含有经批准的药物的纳米胺可以转化为诊所,因此改善了AD患者的生活方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号